PDF herunterladen
Semin Neurol 2011; 31(1): 102-114
DOI: 10.1055/s-0031-1271305
© Thieme Medical Publishers

The Peripheral Neuropathy Evaluation in an Office-Based Neurology Setting

Michael W. Vavra1 , Devon I. Rubin2
  • 1Tri-State Mountain Neurology Associates, Johnson City, Tennessee
  • 2Department of Neurology, Mayo Clinic, Jacksonville, Florida
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. Februar 2011 (online)

    Lizenzen und Reprints

ABSTRACT

Peripheral neuropathy is the most common neuromuscular disorder encountered in a neurologic practice. The evaluation of patients with suspected peripheral neuropathy can be a challenging endeavor for the neurologist. Determining the pattern of clinical involvement and the nerve modalities affected can help to generate a differential diagnosis and design an approach to determine a potential cause. The combination of clinical features, electrodiagnostic testing, and ancillary laboratory studies may be used to determine the etiology. As the most common acquired etiology of peripheral neuropathy is diabetes, careful testing for impaired glucose metabolism is an important part of any diagnostic evaluation.

KEYWORDS

Neuropathy

REFERENCES

  • 1 England J D, Asbury A K. Peripheral neuropathy.  Lancet. 2004;  363 (9427) 2151-2161
    CrossrefPubMedGoogle Scholar
  • 2 Fagius J. Chronic cryptogenic polyneuropathy. The search for a cause.  Acta Neurol Scand. 1983;  67 (3) 173-180
    CrossrefPubMedGoogle Scholar
  • 3 Prineas J. Polyneuropathies of undetermined cause.  Acta Neurol Scand Suppl. 1970;  44 1-72
    PubMedGoogle Scholar
  • 4 Smith A G, Singleton J R. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy.  Arch Intern Med. 2004;  164 (9) 1021-1025
    CrossrefPubMedGoogle Scholar
  • 5 Dyck P J, Oviatt K F, Lambert E H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis.  Ann Neurol. 1981;  10 (3) 222-226
    CrossrefPubMedGoogle Scholar
  • 6 Barohn R J. Approach to peripheral neuropathy and neuronopathy.  Semin Neurol. 1998;  18 (1) 7-18
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.  Neurology. 1991;  41 (5) 617-618
    PubMedGoogle Scholar
  • 8 Joint Task Force of the EFNS and the PNS . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society.  J Peripher Nerv Syst. 2005;  10 (3) 220-228
    CrossrefPubMedGoogle Scholar
  • 9 Haq R U, Fries T J, Pendlebury W W, Kenny M J, Badger G J, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria.  Arch Neurol. 2000;  57 (12) 1745-1750
    CrossrefPubMedGoogle Scholar
  • 10 Hughes R, Bensa S, Willison H Inflammatory Neuropathy Cause and Treatment (INCAT) Group et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 2001;  50 (2) 195-201
    CrossrefPubMedGoogle Scholar
  • 11 Nicolas G, Maisonobe T, Le Forestier N, Léger J M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 2002;  25 (1) 26-30
    CrossrefPubMedGoogle Scholar
  • 12 Thaisetthawatkul P, Logigian E L, Herrmann D N. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy.  Neurology. 2002;  59 (10) 1526-1532
    CrossrefPubMedGoogle Scholar
  • 13 Bromberg M B. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy.  Muscle Nerve. 1991;  14 (10) 968-976
    CrossrefPubMedGoogle Scholar
  • 14 Magda P, Latov N, Brannagan III T H, Weimer L H, Chin R L, Sander H W. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.  Arch Neurol. 2003;  60 (12) 1755-1759
    CrossrefPubMedGoogle Scholar
  • 15 Molenaar D S, Vermeulen M, de Haan R J. Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).  J Neurol. 2002;  249 (4) 400-403
    CrossrefPubMedGoogle Scholar
  • 16 Van den Bergh P Y, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 2004;  29 (4) 565-574
    CrossrefPubMedGoogle Scholar
  • 17 Jann S, Beretta S, Bramerio M, Defanti C A. Prospective follow-up study of chronic polyneuropathy of undetermined cause.  Muscle Nerve. 2001;  24 (9) 1197-1201
    CrossrefPubMedGoogle Scholar
  • 18 Lubec D, Müllbacher W, Finsterer J, Mamoli B. Diagnostic work-up in peripheral neuropathy: an analysis of 171 cases.  Postgrad Med J. 1999;  75 (890) 723-727
    CrossrefPubMedGoogle Scholar
  • 19 Wolfe G I, Baker N S, Amato A A et al.. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics.  Arch Neurol. 1999;  56 (5) 540-547
    CrossrefPubMedGoogle Scholar
  • 20 Notermans N C, Wokke J H, Franssen H et al.. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients.  J Neurol Neurosurg Psychiatry. 1993;  56 (10) 1066-1071
    CrossrefPubMedGoogle Scholar
  • 21 Notermans N C, Wokke J H, van der Graaf Y, Franssen H, van Dijk G W, Jennekens F G. Chronic idiopathic axonal polyneuropathy: a five year follow up.  J Neurol Neurosurg Psychiatry. 1994;  57 (12) 1525-1527
    CrossrefPubMedGoogle Scholar
  • 22 McLeod J G, Tuck R R, Pollard J D, Cameron J, Walsh J C. Chronic polyneuropathy of undetermined cause.  J Neurol Neurosurg Psychiatry. 1984;  47 (5) 530-535
    CrossrefPubMedGoogle Scholar
  • 23 Johannsen L, Smith T, Havsager A M et al.. Evaluation of patients with symptoms suggestive of chronic polyneuropathy.  J Clin Neuromuscul Dis. 2001;  3 (2) 47-52
    CrossrefPubMedGoogle Scholar
  • 24 Saperstein D S, Wolfe G I, Gronseth G S et al.. Challenges in the identification of cobalamin-deficiency polyneuropathy.  Arch Neurol. 2003;  60 (9) 1296-1301
    CrossrefPubMedGoogle Scholar
  • 25 Bednarik J, Vlckova-Moravcova E, Bursova S, Belobradkova J, Dusek L, Sommer C. Etiology of small-fiber neuropathy.  J Peripher Nerv Syst. 2009;  14 (3) 177-183
    CrossrefPubMedGoogle Scholar
  • 26 Sorenson E J, Windebank A J. Hypertriglyceridemia in idiopathic painful small fiber neuropathy.  Neurology. 2000;  54 (Suppl 3) A403
    PubMedGoogle Scholar
  • 27 Singleton J R, Smith A G, Bromberg M B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.  Diabetes Care. 2001;  24 (8) 1448-1453
    CrossrefPubMedGoogle Scholar
  • 28 Hoffman-Snyder C, Smith B E, Ross M A, Hernandez J, Bosch E P. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy.  Arch Neurol. 2006;  63 (8) 1075-1079
    CrossrefPubMedGoogle Scholar
  • 29 Centers for Disease Control and Prevention (CDC) . Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999-2000.  MMWR Morb Mortal Wkly Rep. 2003;  52 (35) 833-837
    PubMedGoogle Scholar
  • 30 Novella S P, Inzucchi S E, Goldstein J M. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy.  Muscle Nerve. 2001;  24 (9) 1229-1231
    CrossrefPubMedGoogle Scholar
  • 31 Gabriel C M, Howard R, Kinsella N et al.. Prospective study of the usefulness of sural nerve biopsy.  J Neurol Neurosurg Psychiatry. 2000;  69 (4) 442-446
    CrossrefPubMedGoogle Scholar
  • 32 England J D, Gronseth G S, Franklin G American Academy of Neurology et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.  Neurology. 2009;  72 (2) 177-184
    CrossrefPubMedGoogle Scholar
  • 33 Hlubocky A, Wellik K, Ross M A et al.. Skin biopsy for diagnosis of small fiber neuropathy: a critically appraised topic.  Neurologist. 2010;  16 (1) 61-63
    CrossrefPubMedGoogle Scholar
  • 34 Koskinen M, Hietaharju A, Kyläniemi M et al.. A quantitative method for the assessment of intraepidermal nerve fibers in small-fiber neuropathy.  J Neurol. 2005;  252 (7) 789-794
    CrossrefPubMedGoogle Scholar
  • 35 Løseth S, Lindal S, Stålberg E, Mellgren S I. Intraepidermal nerve fibre density, quantitative sensory testing and nerve conduction studies in a patient material with symptoms and signs of sensory polyneuropathy.  Eur J Neurol. 2006;  13 (2) 105-111
    CrossrefPubMedGoogle Scholar
  • 36 Shun C T, Chang Y C, Wu H P et al.. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments.  Brain. 2004;  127 (Pt 7) 1593-1605
    CrossrefPubMedGoogle Scholar
  • 37 Sinnreich M, Taylor B V, Dyck P J. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis.  Neurologist. 2005;  11 (2) 63-79
    CrossrefPubMedGoogle Scholar
  • 38 Dyck P J, Kratz K M, Karnes J L et al.. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.  Neurology. 1993;  43 (4) 817-824
    CrossrefPubMedGoogle Scholar
  • 39 Dyck P J, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review.  J Neuropathol Exp Neurol. 1996;  55 (12) 1181-1193
    Google Scholar
  • 40 The Diabetes Control and Complications Trial Research Group . The effect of intensive diabetes therapy on the development and progression of neuropathy.  Ann Intern Med. 1995;  122 (8) 561-568
    PubMedGoogle Scholar
  • 41 Kelly Jr J J, Kyle R A, O'Brien P C, Dyck P J. Prevalence of monoclonal protein in peripheral neuropathy.  Neurology. 1981;  31 (11) 1480-1483
    PubMedGoogle Scholar
  • 42 Latov N, Braun P E, Gross R B, Sherman W H, Penn A S, Chess L. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins.  Proc Natl Acad Sci U S A. 1981;  78 (11) 7139-7142
    CrossrefPubMedGoogle Scholar
  • 43 Latov N, Hays A P, Sherman W H. Peripheral neuropathy and anti-MAG antibodies.  Crit Rev Neurobiol. 1988;  3 (4) 301-332
    PubMedGoogle Scholar
  • 44 Comi G, Roveri L, Swan A Inflammatory Neuropathy Cause and Treatment Group et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.  J Neurol. 2002;  249 (10) 1370-1377
    CrossrefPubMedGoogle Scholar
  • 45 Dalakas M C, Quarles R H, Farrer R G et al.. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.  Ann Neurol. 1996;  40 (5) 792-795
    CrossrefPubMedGoogle Scholar
  • 46 Dyck P J, Low P A, Windebank A J et al.. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.  N Engl J Med. 1991;  325 (21) 1482-1486
    CrossrefPubMedGoogle Scholar
  • 47 Ernerudh J H, Vrethem M, Andersen O, Lindberg C, Berlin G. Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.  J Neurol Neurosurg Psychiatry. 1992;  55 (10) 930-934
    CrossrefPubMedGoogle Scholar
  • 48 Mariette X, Chastang C, Clavelou P, Louboutin J P, Leger J M, Brouet J C. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.  J Neurol Neurosurg Psychiatry. 1997;  63 (1) 28-34
    CrossrefPubMedGoogle Scholar
  • 49 Nobile-Orazio E, Baldini L, Barbieri S et al.. Treatment of patients with neuropathy and anti-MAG IgM M-proteins.  Ann Neurol. 1988;  24 (1) 93-97
    CrossrefPubMedGoogle Scholar
  • 50 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies.  Brain. 2000;  123 (Pt 4) 710-717
    CrossrefPubMedGoogle Scholar
  • 51 Lewis R A. Chronic inflammatory demyelinating polyneuropathy.  Neurol Clin. 2007;  25 (1) 71-87
    CrossrefPubMedGoogle Scholar
  • 52 Ruts L, Drenthen J, Jacobs B C, van Doorn P A. Dutch GBS Study Group . Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.  Neurology. 2010;  74 (21) 1680-1686
    CrossrefPubMedGoogle Scholar
  • 53 Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.  Brain. 1996;  119 (Pt 4) 1067-1077
    CrossrefPubMedGoogle Scholar
  • 54 Dyck P J, Litchy W J, Kratz K M et al.. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 1994;  36 (6) 838-845
    CrossrefPubMedGoogle Scholar
  • 55 Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy.  Autoimmun Rev. 2007;  6 (4) 257-259
    CrossrefPubMedGoogle Scholar
  • 56 Brannagan III T H. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies.  Neurology. 2002;  59 (12, Suppl 6) S33-S40
    CrossrefPubMedGoogle Scholar
  • 57 Klein C J. The inherited neuropathies.  Neurol Clin. 2007;  25 (1) 173-207
    CrossrefPubMedGoogle Scholar
  • 58 Benson M D, Kincaid J C. The molecular biology and clinical features of amyloid neuropathy.  Muscle Nerve. 2007;  36 (4) 411-423
    CrossrefPubMedGoogle Scholar
  • 59 Wierzbicki A S, Lloyd M D, Schofield C J, Feher M D, Gibberd F B. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.  J Neurochem. 2002;  80 (5) 727-735
    CrossrefPubMedGoogle Scholar
  • 60 Pollock M, Nukada H, Frith R W, Simcock J P, Allpress S. Peripheral neuropathy in Tangier disease.  Brain. 1983;  106 (Pt 4) 911-928
    CrossrefPubMedGoogle Scholar
  • 61 Schiffmann R. Fabry disease.  Pharmacol Ther. 2009;  122 (1) 65-77
    CrossrefPubMedGoogle Scholar
  • 62 Albers J W, Fink J K. Porphyric neuropathy.  Muscle Nerve. 2004;  30 (4) 410-422
    CrossrefPubMedGoogle Scholar
  • 63 Hansen L M, Kristensen O, Friis M L. [Neuropathy in adult metachromatic leukodystrophy].  Ugeskr Laeger. 1994;  156 (15) 2252-2253
    PubMedGoogle Scholar
  • 64 Marks H G, Scavina M T, Kolodny E H, Palmieri M, Childs J. Krabbe's disease presenting as a peripheral neuropathy.  Muscle Nerve. 1997;  20 (8) 1024-1028
    CrossrefPubMedGoogle Scholar
  • 65 van Geel B M, Assies J, Wanders R J, Barth P G. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.  J Neurol Neurosurg Psychiatry. 1997;  63 (1) 4-14
    CrossrefPubMedGoogle Scholar
  • 66 Walker R H, Jung H H, Dobson-Stone C et al.. Neurologic phenotypes associated with acanthocytosis.  Neurology. 2007;  68 (2) 92-98
    CrossrefPubMedGoogle Scholar
  • 67 Di Donato S. Multisystem manifestations of mitochondrial disorders.  J Neurol. 2009;  256 (5) 693-710
    CrossrefPubMedGoogle Scholar
  • 68 Bennett C L, Lawson V H, Brickell K L et al.. Late-onset hereditary axonal neuropathies.  Neurology. 2008;  71 (1) 14-20
    CrossrefPubMedGoogle Scholar
  • 69 England J D, Gronseth G S, Franklin G American Academy of Neurology et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.  PM R. 2009;  1 (1) 5-13
    CrossrefPubMedGoogle Scholar
  • 70 Goldstein D J, Lu Y, Detke M J, Lee T C, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy.  Pain. 2005;  116 (1-2) 109-118
    CrossrefPubMedGoogle Scholar
  • 71 Raskin J, Pritchett Y L, Wang F et al.. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.  Pain Med. 2005;  6 (5) 346-356
    CrossrefPubMedGoogle Scholar
  • 72 Lesser H, Sharma U, LaMoreaux L, Poole R M. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.  Neurology. 2004;  63 (11) 2104-2110
    CrossrefPubMedGoogle Scholar
  • 73 Richter R W, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp L E. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.  J Pain. 2005;  6 (4) 253-260
    CrossrefPubMedGoogle Scholar
  • 74 Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.  Pain. 2004;  110 (3) 628-638
    CrossrefPubMedGoogle Scholar

Devon I RubinM.D. 

Department of Neurology, Mayo Clinic

4500 San Pablo Road, Jacksonville, FL 32224

eMail: Rubin.Devon@mayo.edu